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Amyloid-Beta Solubility in the Treatment of Alzheimer’s 
Disease
M. Paul Murphy, Ph.D.
There is general agreement that Alzheimer’s dis­
ease will become a crisis by the middle of the 
century. The Alzheimer’s Association estimates 
that 5 million Americans currently have Alzhei­
mer’s disease and that their loved ones devote 
nearly 18 billion hours annually toward their 
care. If Alzheimer’s disease remains unchecked, 
these numbers are projected to more than triple 
by 2050, and the economic burden will exceed 
$1 trillion per year. The quest to find an effective 
therapy has been urgent. For nearly two decades, 
since the first report of a successful amyloid­
beta (Aβ) immunotherapy in mice,1 this goal has 
seemed tantalizingly close.
In this issue of the Journal, Honig et al.2 report 
the results of the EXPEDITION3 trial of solanezu­
mab, a humanized monoclonal antibody that has 
been designed to clear soluble Aβ from the brain. 
This trial was a follow­up to two earlier trials 
of solanezumab,3 in which secondary analyses 
showed a modest effect in slowing cognitive de­
cline. Unfortunately, the EXPEDITION3 trial did 
not replicate this earlier finding and instead be­
comes another disappointment for amyloid im­
munotherapy. Although several trials of other 
immunotherapies are ongoing, this outcome raises 
several broader issues.
The EXPEDITION3 trial included only patients 
with mild cases of Alzheimer’s disease who had 
some evidence of amyloid disease, as determined 
either by means of f lorbetapir (an 18f luorine­
labeled reagent that binds to Aβ) positron­
emission tomography or by means of cerebro­
spinal fluid measurements of Aβ1­42. Although 
this effort does not differ substantially from 
others that have sought to intervene at an early 
stage of disease, which might be more amenable 
to treatment, it brings up the question, “How 
early is early enough?” Researchers have known 
for some time that the mouse models that we 
rely on to provide preclinical data are much 
closer to humans with prodromal Alzheimer’s 
disease than to persons who have the earliest 
symptomatic stages of the disease.4 A reasonable 
argument has been made that antiamyloid thera­
pies may yet work as a primary preventive strat­
egy.5 For example, persons who have a strong 
family history of Alzheimer’s disease or who 
have a dominantly inherited amyloid mutation 
are motivated participants in clinical trials for 
the prevention of Alzheimer’s disease. Although 
two ongoing trials — DIAN­TU (Dominantly 
Inherited Alzheimer Network Trial, involving 
persons with dominantly inherited mutations; 
ClinicalTrials.gov number, NCT01760005) and 
A4 (Anti­Amyloid Treatment in Asymptomatic 
Alzheimer’s Trial, involving persons at risk for 
Alzheimer’s disease; NCT02008357) — will par­
tially address the question of amyloid removal in 
disease prevention, we are still several years 
from knowing their results.
The trial conducted by Honig et al. could 
point to an alternative possibility, one that is 
potentially more promising (or at least intrigu­
ing). The authors point out that solanezumab 
was highly effective at targeting soluble Aβ. Al­
though it is possible that the magnitude of re­
duction in soluble Aβ was simply insufficient to 
create a measurable clinical benefit, recent re­
sults from an early trial of aducanumab could 
indicate that the ability of an antiamyloid therapy 
to clear insoluble Aβ is an important factor in 
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the success of treatment.6 If clearing previously 
deposited amyloid from the brain is more impor­
tant than preventing its production, this could 
also at least partially explain the lack of success 
with other strategies such as beta­secretase in­
hibitors that have, after initial promise,7 proved 
disappointing.8 It is also possible that some 
other characteristic of aducanumab, such as its 
relatively higher penetration in the brain, as com­
pared with solanezumab, explains the difference. 
A final determination rests on the outcome 
of ongoing studies of aducanumab (ENGAGE 
[NCT02477800] and EMERGE [NCT02484547]), 
which expand the scope to an international trial 
(at different sites).
Although it may not quite be time to give up 
on Aβ immunotherapy for treating Alzheimer’s 
disease, it would be foolish to ignore the contin­
ued failures of antiamyloid approaches. In spite 
of the mountain of evidence supporting the 
primacy of Aβ in Alzheimer’s disease, many re­
searchers are coming to the realization that our 
preclinical models of the disease may be miss­
ing the mark. Even if there is some future suc­
cess in a primary prevention trial, there is still 
little headway being made in improving the 
treatment of Alzheimer’s disease. There is some 
hope that a combination of therapeutic approach­
es might help, since there is evidence that the 
different pathologic aspects of Alzheimer’s dis­
ease are interactive.9 Whether a multifaceted 
strategy or something entirely unforeseen is the 
answer, the field is clearly in need of innovative 
ideas. We may very well be nearing the end of 
the amyloid­hypothesis rope, at which point one 
or two more failures will cause us to loosen our 
grip and let go.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
From the Department of Molecular and Cellular Biochemistry 
and the Sanders-Brown Center on Aging, University of Ken-
tucky Medical Center, Lexington. 
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Progress in the Treatment of Hodgkin’s Lymphoma
Dan L. Longo, M.D., and Vincent T. DeVita, Jr., M.D.
Although there has been considerable research 
activity in the treatment of Hodgkin’s lymphoma 
since advanced stages of the disease became 
curable with combination chemotherapy in the 
1960s, the most significant advances have in­
volved the maintenance of a particular level of 
antitumor efficacy while acute and late toxic side 
effects and their attendant mortality are reduced. 
These advances include the preservation of high 
response rates at reduced levels of toxicity with 
the current standard regimen of doxorubicin, 
bleomycin, vinblastine, and dacarbazine (ABVD); 
the demonstration that various forms of radia­
tion therapy were associated with unacceptably 
high levels of long­term toxicity; the application 
of high­dose salvage chemotherapy; and the tailor­
ing of treatment to the evidence of response re­
vealed on midterm positron­emission tomogra­
phy (PET). Little progress has been made in 
improving overall survival.
Two notable exceptions to this general lack of 
progress in the development of newer approach­
es to treatment are the application of the CD30 
immunotoxin brentuximab vedotin1 and the pro­
grammed death 1–inhibitor nivolumab2 to the 
treatment of patients with Hodgkin’s lymphoma 
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